Fero gets Mexico certification for pre-mixed raw Sucanon tabletization, packaging

Initial shipments of pre-mixed Sucanon from Canada have already commenced, totaling five (5) containers – the equivalent of 6,000,000 tablets or 100,000 one-month patient supplies.

Fero Industries has acquired the rights to Sucanon, a member of a class of diabetic medications called insulin sensitizers.

Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars.

Pre-clinical and clinical studies showed that Sucanon and other insulin sensitizers lower a patient’s blood sugar by increasing the muscle, fat and liver’s sensitivity to the body’s own naturally produced insulin.

Sucanon is currently approved as an over-the-counter (OTC) remedy for Type II diabetes by regulatory authorities in Mexico.

Sucanon is distributed under an exclusive agreement with Merck SA, the Mexico and Latin America sales and marketing organization of German pharmaceutical and chemical giant, Merck, in Mexico.

Commercial launch and sales of Sucanon in Mexico are expected to commence in early January 2011.

Fero Industries president and CEO Kyle Schlosser said manufacturing Sucanon in Canada for final tabletization and packaging in Mexico allows us to maintain strict product control while avoiding several potential import/export related delays.

"This ensures our ability to fulfill our current Mexico distribution contract with Merck SA and support expanding global sales efforts," Schlosser said.